Immunogenic Peptides as Vaccines against Herpes Simplex Virus

Tech ID: 24268 / UC Case 2014-219-0

Brief Description

Immunogenic peptides isolated from HSV seropositive asymptomatic (ASYMP) individuals induce a CD8+ T cell- dependent protective immunity against herpes virus in a mammal.

Full Description

Individuals that carry Herpes Simplex Virus type 1 (HSV-1) and/or Herpes Simplex Virus type 2 (HSV-2) can be symptomatic (SYMP) and suffer a wide range of HSV conditions on a recurrent basis throughout their lives. There is no cure for HSV infection. Clinically effective treatments for the inhibition of HSV infection and/or amelioration of HSV conditions are needed.

Researchers at UC Irvine identified the epitopes from the ASYMP individuals by the genome-based bioinformatics searches and the prediction algorithms. Peptides that were synthesized based on the corresponding epitopes bound to HLA-A*02:01 molecules with high affinity. Immunization of these peptides induced CD8+ T cells–dependent protective immunity against ocular herpes infection and disease in “humanized” HLA-A*02:01 transgenic mice. These findings should guide the development of a safe and effective T-cell-based herpes vaccine

The following figure is a plot of the percent survival of SYMP, ASYMP, and MOCK group mice.

SYMP, ASYMP, MOCK survival

Suggested uses

The information of ASYMP epitopes and synthesized peptides based on them can be used to develop HSV vaccine.


In the mice model, the ASYMP epitopes:

  • Decreased ocular herpes disease,
  • Decreased virus replication
  • Protected against lethal ocular herpes

Patent Status

Country Type Number Dated Case
United States Of America Issued Patent 9,878,033 01/30/2018 2014-219

Related Materials


Learn About UC TechAlerts - Save Searches and receive new technology matches

Other Information

Categorized As

  • Institute for Innovation Logo
  • Institute for Innovation Logo

University of California, Irvine Invention Transfer Group
5141 California Avenue, Suite 200, Irvine,CA 92697-7700
Tel: 949.824.2683 | Fax: 949.824.3880 |

© 2014 - 2018, The Regents of the University of California
Terms of use | Privacy Notice